Document is current
Any future updates will be listed below
-
Authors
Reps, Jenna M. http://orcid.org/0000-0002-2970-0778
Rijnbeek, Peter
Cuthbert, Alana
Ryan, Patrick B.
Pratt, Nicole
Schuemie, Martijn
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (806968)
- License Information
-
More Information
Article History
Received: 5 August 2020
Accepted: 25 January 2021
First Online: 6 February 2021
Ethics approval and consent to participate
: All patient data included in this study were deidentified. The New England Institutional Review Board determined that studies conducted in Optum are exempt from study-specific IRB review, as these studies do not qualify as human subjects research.
: Not applicable.
: Jenna Reps is an employee of Janssen Research and Development and shareholder of Johnson and Johnson. Patrick Ryan is an employee of Janssen Research and Development and shareholder of Johnson and Johnson. Martijn Schuemie is an employee of Janssen Research and Development and shareholder of Johnson and Johnson. Peter Rijnbeek works for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research and Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.
